Ever Supreme Bio Technology Co. Ltd
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company's products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the… Read more
Ever Supreme Bio Technology Co. Ltd (6712) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.035x
Based on the latest financial reports, Ever Supreme Bio Technology Co. Ltd (6712) has a cash flow conversion efficiency ratio of 0.035x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.51 Million) by net assets (NT$1.54 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ever Supreme Bio Technology Co. Ltd - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Ever Supreme Bio Technology Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ever Supreme Bio Technology Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ever Supreme Bio Technology Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Jianan Electronics Co Ltd
SHE:300880
|
0.079x |
|
ZINZINO AB B
F:9EE
|
N/A |
|
Multiconsult ASA
LSE:0R8N
|
0.105x |
|
Jiangsu Beiren Robot System Co Ltd
SHG:688218
|
N/A |
|
Zhejiang Jinfei Kaida Wheel Co Ltd
SHE:002863
|
0.040x |
|
Shihlin Paper Corp
TW:1903
|
0.023x |
|
Shenzhen Zhongheng Huafa Co Ltd Class A
SHE:000020
|
-0.033x |
|
Besalco Sa
SN:BESALCO
|
0.062x |
Annual Cash Flow Conversion Efficiency for Ever Supreme Bio Technology Co. Ltd (2020–2023)
The table below shows the annual cash flow conversion efficiency of Ever Supreme Bio Technology Co. Ltd from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$1.84 Billion | NT$421.74 Million | 0.229x | +28.48% |
| 2022-12-31 | NT$1.79 Billion | NT$319.20 Million | 0.178x | +149.11% |
| 2021-12-31 | NT$1.90 Billion | NT$135.69 Million | 0.071x | +140.31% |
| 2020-12-31 | NT$780.76 Million | NT$-138.47 Million | -0.177x | -- |